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Telomerase comprises a reverse transcriptase and
an internal RNA template that maintains telomeres
in many eukaryotes, and it is a well-validated cancer
target. However, there is a dearth of small molecules
with efficacy against human telomerase in vivo.
We developed a surrogate yeast high-throughput
assay to identify human telomerase inhibitors. The
reversibility of growth arrest induced by active
human telomerase was assessed against a library
of 678 compounds preselected for bioactivity in
S. cerevisiae. Four of eight compounds identified
reproducibly restored growth to strains expressing
active human telomerase, and three of these
four compounds also specifically inhibited purified
human telomerase in vitro. These compounds repre-
sent probes for human telomerase function, and
potential entry points for development of lead
compounds against telomerase-positive cancers.
INTRODUCTION
The reactivation of telomerase is important for cancer cell
survival. While primary somatic cells do not normally express
telomerase and undergo progressive telomere shortening that
leads subsequently to cell senescence, many malignant cell
types activate telomerase expression to counteract telomere
attrition and support tumor growth. Given its selective expres-
sion in cancer and requirement for cell immortality, telomerase
in principle represents an ideal therapeutic cancer target (Harley,
2008). Mounting preclinical and clinical data strongly suggest
that telomerase inhibition is a viable approach to suppress
cancer progression, particularly in cancer cells with shorter telo-
meres, low telomerase expression, and rapid turnover (Harley,
2008). Furthermore, telomerase inhibition augments the sensi-
tivity of carcinoma cell lines to radiation therapy and cytotoxic
drugs (Gomez-Millan et al., 2007; Ro¨th et al., 2010; Ward and
Autexier, 2005).
Approaches to inhibit telomerase in cancer cells include direct
or indirect enzyme inhibition though gene therapy, oligonucleo-Chemistry & Biology 20, 3tides that are complementary to the RNA template, and small
molecule antagonists of enzyme activity (Harley, 2008). The
most potent known in vitro telomerase inhibitor, BIBR1532 is
a nonnucleosidic compound that interferes with the processivity
of telomere elongation; however, BIBR1532 has not been taken
into clinical trials due to issues with solubility and bioavailability
(Damm et al., 2001; El-Daly et al., 2005; Pascolo et al., 2002).
Imetelstat (GRN163L) is an oligonucleotide template antagonist
that targets the active site of human telomerase through the telo-
merase RNA (hTR) template region and is the only telomerase
inhibitor of its class to have progressed to phase II clinical trial
(Ro¨th et al., 2010; Harley, 2008). Thus, there remains a pressing
need for the development of additional candidate telomerase
inhibitors for cancer treatment.
Here, we report a surrogate genetic screening assay for
human telomerase activity based on conditional heterologous
expression of the two core catalytic subunits of the human ribo-
nucleoprotein (RNP), hTR and telomerase reverse transcriptase
(hTERT) in budding yeast (Bachand and Autexier, 1999; Bah
et al., 2004). When hTERT is tethered to the yeast telomere via
fusion with a yeast telomeric DNA binding protein, Cdc13,
growth arrest occurs upon coexpression with hTR (Bachand
and Autexier, 1999; Bah et al., 2004). We exploited this inducible
growth arrest phenotype in a high-throughput assay to identify
three compounds that reverse growth suppression via the
specific inhibition of human telomerase.
RESULTS
Induction of Active HumanRelomerase in Budding Yeast
To reconstitute functional human telomerase in S. cerevisiae,
we introduced phTR, for constitutive expression of hTR, and
pGAL1-CDC13-hTERT-FLAG, to permit galactose-inducible ex-
pression of CDC13-TERT-FLAG (Bah et al., 2004; Evans and
Lundblad, 1999) (Figure S1A available online). Expression of
hTR and Cdc13-hTERT-FLAG in galactose-containing medium
was confirmed by reverse transcriptase (RT)-PCR and western
blot (Figures 1A and 1B). Galactose induction of CDC13-TERT-
FLAG resulted inmicrocolony formation and growth suppression
by 48 hr, and persisted up to 96 hr (Figures 1C and S1C). No
growth delay was observed during the first 24 hr, likely due to
a lag in the assembly and recruitment of active human telome-
rase to levels sufficient to induce a response (Figure S2A; data
not shown). As expected, strains expressing hTR alone, which33–340, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 333
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A Yeast Chemical Screen against Human Telomeraseis insufficient for human telomerase activity in yeast (Bah et al.,
2004), exhibited no growth delay (Figure 1C). The growth imped-
ance caused by human telomerase expression depended upon
the presence of the ATM-like kinase Mec1, which is the predom-
inant DNA damage checkpoint kinase in budding yeast (d’Adda
di Fagagna et al., 2004) (Figures 1D and S1E). The arrest did not
depend on Esc4, a key factor in DNA replication restart that is
dispensable for the intra-S-phase checkpoint arrest (Rouse,
2004) (Figure 1E). Expression of human telomerase did not inter-
fere with endogenous yeast telomerase function, since there
were no changes in the terminal telomere DNA-containing
restriction fragment (TRF) length and no human telomeric
repeats were detected at yeast telomeres (Figure S1D; data
not shown) (Bah et al., 2004). Unlike the Mec1-dependent, irre-
versible arrest in response to a double-strand break at a native
yeast telomere (Sandell and Zakian, 1993), the growth inhibition
induced by human telomerase was reversible, and growth
resumed if glucose was added to the medium to suppress
CDC13-TERT-FLAG (Figure S1H).
To confirm the specificity of the inducible growth suppres-
sion, we assessed the effect of mutations in the cDNAs encoding
hTR, hTERT, and Cdc13 upon growth after confirmation that the
mutant mRNA and proteins were expressed at levels compa-
rable to their wild-type counterparts (Figures S1F and S1G). A
10-nucleotide (nt) substitution between nts 190 and 199 was
introduced into hTR (hTR190), rendering it catalytically inactive
(Autexier et al., 1996). Two mutations of hTERT were also intro-
duced: the first (TERT1–677) lacks RT motifs essential for activity
(Banik et al., 2002), and the second (hTERT-D868A-FLAG)
contains an alanine substitution at D868, a residue essential
for activity (Harrington et al., 1997). Finally, the telomere DNA
binding domain within Cdc13, which is essential for its telomere
recruitment (Evans and Lundblad, 1999), was removed from the
hTERT fusion protein. All four mutations abolished the growth
arrest (Figure 1F). Thus, the arrest depended on telomere recruit-
ment and the catalytic activity of human telomerase conferred by
hTR and hTERT.
A Yeast-Based HTS for Human Telomerase Inhibitors
We used a Tecan shaker-reader platform to establish conditions
in a 96-well format (Figure 2A) that recapitulated the growth delay
specific to active human telomerase (compare Figure 2B and
Figure 1F). Expression of hTERT and hTR was confirmed, and,
as anticipated, no growth delay was observed during the first
39 hr of growth (this preassay phase is hereinafter referred toFigure 1. Reconstitution of Active Human Telomerase in S. cerevisiae
(A) RT-PCR analysis of hTR expression from total cellular RNA (30 ng) prepared fr
media containing galactose (gal; lanes 5–7) or glucose (glc; lanes 8–10), and, as a
lanes between lanes 7–8 and 9–10 were omitted. RT, reverse transcriptase; Taq
(B) Immunoprecipitation (IP) of 500 mg crude lysate onto anti-FLAG resin follow
noninducible (raffinose, raf), repressive (glc), and galactose-containing (gal) media
at right. Asterisk indicates immunoglobulin G heavy chain (53 kDa) of anti-FLAG
(C) Cell number during an 8-day growth period of W303-1a in galactose (gal) or glu
vector), hTR alone (hTR), or Cdc13-hTERT-FLAG and hTR. Error bars indicate S
(D) Growth analysis as in (C) in strains expressing Cdc13-hTERT-FLAG + hTR in
(E) Growth analysis as in (C) in strains expressing Cdc13-hTERT-FLAG + hTR in
(F) Cell number after 2 days of growth of W303-1a strains expressing an inactive
(containing an amino acid substitution in the catalytic site, D868A), or lacking the
See also Figure S1 and Table S1.
Chemistry & Biology 20, 3as time course 1) (Figures S2A and S2B). Following an additional
86 hr (the experimental growth assay phase, hereinafter referred
to as time course 2), strains expressing catalytically active
human telomerase (Cdc13-hTERT-FLAG + hTR) exhibited a
delay in exponential phase growth when compared to a strain
expressing inactive telomerase (hTERT-D868/A868) (Figure 2B).
Using an optical density at 595 nm (OD595) of 0.62 as a reference
for the midpoint of exponential phase (see Figure S2B), cells
expressing Cdc13-hTERT-FLAG + hTR reached this OD an
average of 8.75 hr later during time course 2 than strains ex-
pressing inactive hTERT [Cdc13-hTERT(D868A)-FLAG + hTR].
We next screened two independent replicates of a library of
678 bioactive compounds against the query strain expressing
active human telomerase and compared growth to the same
strain treated with 2% v/v dimethyl sulfoxide (DMSO). These
678 compounds were selected from a 50,000 member May-
bridge library based upon a spectrum of growth inhibitory bioac-
tivity in a drug pump-deficient yeast strain (Ishizaki et al., 2010).
This bioactive library yields a hit rate of 12% in a HeLa cell prolif-
eration assay, such that most of the compounds are nontoxic to
human cells at the screening concentration used (M.S., JanWild-
enhain, Sonam Dolma, David Bellows, and M.T., unpublished
data). In each 96-well assay plate, growth of the query strain in
the presence of compound (20 mM), beginning at the onset of
the experimental growth phase (i.e., time course 2, from 43 hr
onward), was normalized against DMSO treatment (Figures 2C
and 2D; Figures S2D and S2E). As expected, the growth rate
of the query strain was consistent between both screens and
individual assay plates upon treatment with DMSO (Figure S2D);
however, the growth rates upon treatment with compounds
between the two screens was more variable, with a Pearson
correlation coefficient of 0.4 (Figure S2E). Relative to DMSO,
a total of eight compounds rescued the time to reach an OD595
of 0.62 by at least 8 hr (Figure 2C), with a predicted false-positive
rate of 1.4% (see Experimental Procedures). Follow-up screens
that included the eight putative hits (and 43 other compounds
that did not initially meet the 8-hr threshold) confirmed that
three of the eight high-throughput screen (HTS) hits reproducibly
and specifically advanced the growth rate of strains expressing
active human telomerase (Table 1; Figure 2E; see Supplemental
Experimental Procedures for details). One of the rescreened
compounds, SEW05920, did not exhibit significant growth
recovery in the initial HTS but exhibited a growth recovery of
8 hr in follow-up screens and inhibited telomerase activity
in vitro (Table 1; Figures 2E and 3). In contrast, the knownvia Coexpression of Wild-Type Cdc13-hTERT-FLAG and hTR
om a W303-1a strain containing pCDC13-hTERT-FLAG and phTR plasmids in
control, hTR synthesized in vitro (lanes 1–3; 0.5 ng, 0.2 ng, 0.05 ng). Irrelevant
, Taq polymerase; M, DNA markers.
ed by detection with anti-FLAG (Oulton and Harrington, 2004) after growth in
. The predictedmass of Cdc13-hTERT-FLAG is 232 kDa, indicated by the arrow
antibody.
cose (glc) or W303-1a in galactose containing an emptyGAL1 plasmid (empty
D, n = 3.
a mec1D sml1D strain background. Error bars indicate SD, n = 3.
an esc4D strain background. Error bars indicate SD, n = 3.
hTR mutant (hTR190), truncated, inactive hTERT (TERT1–677), inactive hTERT
DNA-binding domain (DBD) of Cdc13. Error bars indicate SD, n = 3.
33–340, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 335
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Table 1. Screen Hits and Corresponding Z Score Values
Compounds
Time (hr) Difference at an OD595 of 0.62
Relative to DMSO Z Score
CD11359 8.3 1.7
SPB03924 12 2.3
RJC00417 10 2.0
SEW05920 8.3a 1.7
aSEW05920 did not significantly rescue growth in the initial HTS
analysis but was validated as a hit based on significant growth recovery
in two follow-up subscreens and upon repurchase of the compound from
the commercial supplier. Please refer to Supplemental Experimental
Procedures.
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A Yeast Chemical Screen against Human Telomerasein vitro telomerase inhibitor, BIBR1532 (Figures 3A and S2F), had
no effect upon the growth of control strains or yeast expressing
human telomerase (Figure 2F). Furthermore, in a hyperpermeable
strain, pdr1DBD-cyc8 (Stepanov et al., 2008), BIBR1532 was
toxic (Figure S2G).
In Vitro Characterization of Inhibitors Specific to Human
Telomerase
We found that three of the four compounds (SEW05920,
SPB03924, and CD11359) exhibited a dose-dependent inhibi-
tion of both purified recombinant human telomerase and telome-
rase activity in crude HeLa cell extracts using a telomerase
repeat amplification protocol (TRAP) assay (Figures 3A–3C).
The fourth compound, RJC00417, did not inhibit telomerase
activity in vitro and thus may inhibit human telomerase in yeast
through a mechanism distinct from catalytic inhibition (Fig-
ure 3B). As a control, we observed no inhibition of the Taq
polymerase used for amplification of telomerase extension
products in the TRAP (data not shown). In addition, as negative
controls, two other compounds that were not identified as hits
(SPB03922 and RH00646) were tested and confirmed to exert
no effect upon telomerase activity in vitro (Figure 3B). Using
a semiquantitative assay for the detection of telomerase elonga-
tion products (ELISA-TRAP) the in vitro half maximal inhibitory
concentration (IC50) values of the compounds fell between 1
and 6.5 mM (Figures 3C and 3D). Similar IC50 values were
also observed against purified recombinant murine telomeraseFigure 2. High-Throughput Chemical Screens of W303-1a Expressing
(A) Schematic of HTS design. Cells induced with active human telomerase were di
OD595 was assessed throughout two serial time courses that totaled 128 elaps
(B) Growth profiles in a 96-well format, obtained with a Tecan shaker-reader, of W
inactive hTERT mutant (D868A) + hTR during time course 2 (commencing at 43 h
Horizontal double-sided arrow indicates the relative growth delay of 8.75 hr betw
(C) Histogram of the number of compounds in categories of time difference (hr) to
2, dark gray). Compounds that rescued relative growth delay by between 8 and
(D) Heatmap analysis of time difference (hr) to reach an OD595 of 0.62 relative to D
cycloheximide; D, DMSO.Wells containing compounds (or cycloheximide) that im
the time to reach an OD595 of 0.62 relative to DMSO was advanced by 8 hr or m
(E) Fold change in time difference (hr) to reach an OD595 of 0.62 relative to DMSO
truncation (Cdc13-TERT1–677 + hTR), or Cdc13 lacking its DNA binding doma
compounds (20 mM). Values were normalized to the time rescue observed in strai
with DMSO. Error bars indicate SD, n = 4.
(F) Growth profiles ofW303-1a cells alone (left) or expressing wild-type Cdc13-hTE
of treatment during time course 1, then 3 hr in galactose only, and readdition of c
2% v/v DMSO. Error bars indicate SD, n = 3.
See also Figure S2.
Chemistry & Biology 20, 3(data not shown). These values are higher than that of
BIBR1532 (IC50 = 0.1 mM) (Damm et al., 2001; Pascolo et al.,
2002) but within a concentration range typical of first hits from
commercial libraries. SEW05920, SPB03924, and CD11359 are
heteroaromatic small molecules that differ structurally from
BIBR1532 (Figures 3A and S2F). A search of PubChem revealed
that SEW05920 had not been registered in a previous bioassay;
similarly, CD11359 and SPB03924 were screened in nine and 14
bioassays, respectively, against diverse targets including toll-
like receptor 4, Sphingosine 1-Phosphate receptor 1, NADPH
oxidase 1, phosphatase methylesterase 1, and NOTCH1 but
were not identified as hits.
DISCUSSION
Analysis of human enzymatic activity as a direct output of a high-
throughput screen in yeast has been used previously (Ceyhan
et al., 2012; Griffioen et al., 2006; Perkins et al., 2001). Our results
extend the utility of budding yeast as a model system to identify
and validate compounds, in particular, its utility for a large multi-
subunit RNP enzyme (383 kDa, including hTERT-Cdc13 and
hTR). This surrogate genetic system possesses several advan-
tages over conventional chemical screening approaches. The
yeast-based assay obviates the need for large quantities of puri-
fied human telomerase in vitro and allows the facile incorporation
of mutational controls. The heterologous expression system
enables human telomerase to be specifically targeted, unlike
human cell line-based assays, and therefore allows rapid coun-
terselection against compounds that exhibit off-target effects on
cell growth. The yeast system also selects for bioactive small
molecules with well-balanced hydrophilic-lipophilic properties
due to the presence of two chemically different barriers, namely,
the hydrophilic polysaccharide wall and the lipophilic phospho-
lipid membrane. Notably, the compound library used in this
study was already highly enriched for yeast cell bioavailability,
which allows a substantially higher hit rate that conventional
library screens (Ishizaki et al., 2010).
Aside from the general features of planar, aromatic groups that
typify the Maybridge compound collection, the three putative
telomerase inhibitors span diverse chemical classes that do
not coincide with known telomerase inhibitors (Harley, 2008).Cdc13-hTERT-FLAG + hTR
spensed in assay plates with media containing galactose and compounds, and
ed hr (see Experimental Procedures for details).
303-1a cells expressing wild-type Cdc13-hTERT-FLAG + hTR or a catalytically
r in culture, labels spaced every 4.5 hr and rounded up or down accordingly).
een the two strains at an OD595 of 0.62. Error bars, in black, indicate SD, n = 8.
reach an OD595 of 0.62 relative to DMSO treatment (screen 1, light gray; screen
16 hr are shown in pink or red.
MSO in a representative 96-well plate during the assay phase time course 2. C,
peded growth by more than 8 hr relative to DMSO appear white. Wells in which
ore are red (e.g., CD11359, outlined in black).
of strains expressing active hTERT (Cdc13-hTERT + hTR), an inactive hTERT
in [Cdc13(-DBD)-hTERT + hTR] in the presence of repurchased candidate
ns expressing catalytically inactive Cdc13-hTERT(D868A)-FLAG + hTR treated
RT-FLAG+ hTR (right) commencing at 35 hr after induction (i.e., following 32 hr
ompound or DMSO at 35 hr) containing 500, 150, 50, 10, or 1 mM BIBR1532 or
33–340, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 337
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Figure 3. Assessment of Human Telomerase Inhibition In Vitro
(A) Chemical structures of BIBR1532 and hit compounds SEW05920, SPB03924, and CD11359.
(B) Representative gel of the telomerase repeat addition protocol (TRAPeze, Millipore) after addition of RJC00417, SEW05920, SPB03922, and RH00646 to
recombinant human telomerase purified in vitro (Beattie et al., 1998; Oulton and Harrington, 2004) (n = 3). Lanes 1–5, treatment with 200, 100, 20, 10, or 2 mM
RJC00417; lanes 6–10, treatment with 200, 100, 20, 10, or 2 mM SEW05920; lanes 11–15, treatment with 200, 100, 20, 10, or 2 mM SPB03922; lanes 16–20,
treatment with 200, 100, 20, 10, or 2 mM RH00646; lane 21, treatment with 2% v/v DMSO; lane 22, pretreatment with ribonuclease A. IC; internal PCR control
(36 base pairs [bp]).
(C) Representative gel of the relative telomerase activity (RTA) by ELISA-TRAP (TeloTAGGGTelomerase PCR ELISA-PLUS, RocheDiagnostics) of purified human
telomerase upon incubation with BIBR1532 (lanes 1–4), SEW05920 (lanes 5–8), SPB03924 (lanes 11–14), CD11359 (lanes 15–18) (concentration indicated in
micromolar), 2% v/v DMSO (lane 9), or heat (lane 10). IC; internal PCR control (216 bp).
(D) Levels of RTA (%) after normalization to a 216 bp internal control, as shown in (C). Error bars indicate SD, n = 3.
For synthesis of BIBR1532, see Figure S2.
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positive or telomerase-negative cell lines with long telomeres
(Sealey et al., 2010; Taboski et al., 2012) over a concentration
range of 0.5–5.0 mM after 28–35 days of continuous treatment
(data not shown). Although nontoxic, longer treatment periods
will be required to detect telomere shortening in human cells,
since significant shortening in the presence of GRN163L can
take up to 3 months (Uziel et al., 2010). The chemical properties
of SEW05920, SPB03924, and CD11359 appear amenable to
structure-activity-relationship analysis, which will enable the
design and synthesis of more potent derivatives to be tested
for efficacy in telomerase-positive human cancer cell lines, and
for determination of their precise mechanism of action in vitro.
SIGNIFICANCE
The specificity of yeast growth suppression for active
human telomerase will also enable the screening of active
hTERT variants capable of drug resistance. We note that
acquired drug resistance to single-drug regimes against
HIV reverse transcriptase is a prevalent concern in the
treatment of HIV infection (Penazzato and Giaquinto, 2011).
The diverse compound structures recovered in the screen
suggest the possibility that more than one site can be tar-
geted on active telomerase. Combinations of inhibitors
with different mechanisms of action may exhibit additive or
synergistic inhibition and impede the emergence of single-
point mutations in hTERT that are drug resistant. The surro-
gate budding yeast system thus provides a sensitive and
cost-effective assay for the identification of human telome-
rase inhibitors and will accelerate classical hit-to-lead
chemistry in parallel with testing in human cell lines and
animal models.
EXPERIMENTAL PROCEDURES
Construction of pGAL1-CDC13-hTERT-FLAG and phTR Plasmids
Human TERT-FLAG cDNAwas PCR amplified frompCR3-FLAG-hTERT-FLAG
(Beattie et al., 1998) and inserted downstream of the 30 terminal 1.2 kilobase
pairs (kbp) of CDC13 in an intermediate StrataClone vector, to which the
terminator sequence of the ADH1 gene (ADHter) was subsequently inserted
downstream of the fusion protein. This fragment, CDC13SphI-hTERT-ADHter,
was inserted into pGAL1-pVL1091 (Evans and Lundblad, 1999). The hTR
sequence was amplified from pUC19-hTR (Beattie et al., 2000), digested
with EcoRI, and inserted into pIII426 (Good and Engelke, 1994). The final
constructs were verified by DNA sequencing.
Galactose Induction and Growth Assay
W303-1a haploid cells, MATa ade2-1 trp1-1 leu2-3,112 his3-11,15 ura3-1
can1-100 (Thomas and Rothstein, 1989), or a mec1D sml1D strain, MATa
ura3-52 trp1-289 leu2-3,112 bar1::LEU2 (Makovets et al., 2004; Zhao et al.,
1998), were transformed with pCDC13-hTERT-FLAG and phTR plasmids
(Gietz and Woods, 2002) and were propagated on synthetic dropout liquid
medium lacking uracil and leucine and containing 3% (w/v) raffinose. At an
OD 600 (OD600) of 0.3, cells were pelleted, washed, and resuspended in selec-
tive media containing 2% (w/v) galactose (to induce expression of Cdc13-
hTERT-FLAG) or 2% (w/v) glucose.
Cdc13-hTERT-FLAG and hTR Expression by RT-PCR Analysis
Total cellular RNA was isolated as described by Burke et al. (2000) and
amplified using the Sensiscript RT Kit protocol (QIAGEN); hTR, forward:
50-GGGTTGCGGAGGGTGGGCC-30, reverse: 50-GCATGTGTGAGCCGAGTCChemistry & Biology 20, 3CTGG-30; hTERT, forward 50-GCGAGCTGCGGTCACCCC-30, reverse 50- AG
CTCCTGCAGCGAGAGC-30; Act1, forward 50- ATGGATTCTGAGGTTGCTG
CTTTGGTTA-30, reverse 50- TGTTCTTCTGGGGCAACTCTCAATT-30.
High-Throughput Chemical Screens
W303-1a cells bearing pCDC13-hTERT-FLAG and phTR plasmids were grown
in selective medium containing 3% (w/v) raffinose until an OD600 of 0.3, fol-
lowed by a 2 hr pregrowth in medium containing 2% (w/v) galactose prior to
addition of compounds. To conduct the HTS (Figure 2A), 98 ml (3 3 105 cells
per milliliter) was dispensed into 96-well clear flat-bottomed microplates
(Corning Costar) using a Biomek FX (Beckman Coulter). A small molecule
bioactive library of 678 compounds was utilized for the screen, consisting of
compounds selected from theMaybridge collection (Thermo Fisher Scientific).
Two microliters of each compound from the master library plate was
dispensed into the assay plate at a final concentration of 20 mM, 2% (v/v)
DMSO. DMSO at 2% (v/v) and 20 mM cycloheximide (Sigma) final concentra-
tion were added as controls to each assay plate, into alternate wells in columns
1 and 12 using the Span 8 module of the Biomek FX. Nine plates were
analyzed, 80 compounds per plate, with 16 wells for controls. After compound
addition, the plates were sealed and followed for time course 1 (up to 39 hr) on
a Sunrise plate reader (Tecan) at absorbance 595 nm, maintained at 30C and
shaking at 564 rpm. After time course 1, cells in assay plates were diluted to
33 105 cells per milliliter in freshmedia containing galactose using the Biomek
FX. The plates were preincubated in galactose-containing media at 30C for
3 hr (to allow a period of recovery from the stationary phase in the absence
of compound), 2 ml of each compound or control was added to plates as
described earlier, returned to the plate readers, and followed for time course
2 (up to 86 hr), for a total of 128 elapsed hours. In follow-up experiments,
we confirmed that the ability of a validated hit (SPB03924) to accelerate growth
recovery did not differ significantly when the compound was added immedi-
ately at the outset of time course 2 versus its readdition after a 3 hr period in
galactose only (data not shown).
Identification of Human Telomerase Inhibitors
Growth curves were analyzed using a growth curve analysis tool implemented
in R. After smoothing of growth curves, the time required for cells induced with
human telomerase to reach an OD595 of 0.62 in the presence of each
compound during time course 2 was derived using a data-based approach
(Warringer and Blomberg, 2003). The time to reach an OD595 of 0.62 for
each compound was normalized to the average DMSO value from each assay
plate (to arrive at a normalized value, x, for each compound) and used to
generate heatmaps as shown in Figure 2C. Z scores were calculated based
on the equation: z = (x  m)/s, where m is the mean time difference for all
compounds in the bioactive library and s is the SD for all compounds in the
bioactive library. The rate of false-positives (1.4%) was estimated based on
the number of DMSO-treated wells that were able to accelerate the time to
reach an OD595 of 0.62 by 8 hr or more, using the following equation: 1 
(atrue-positives/btotal) 3 100%, where a corresponds to the number of DMSO
controls that exhibited a rescue in growth equal to or above 8 hr and b corre-
sponds to the total number of DMSO controls included in the screen. Four
follow-up subscreens were performed after the high-throughput screen,
leading to the identification of the validated hit compounds listed in Table 1.
These compounds were also analyzed for their ability to inhibit human telome-
rase activity in vitro (see Supplemental Experimental Procedures for details).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, Supplemental Experimental
Procedures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2012.12.008.
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